Leftover stocks of high-priced medicines are emerging as a serious headache for Japanese pharmacies, fueling financial stress and even bankruptcies…
HOME > June 16, 2025
Daily News
June 16, 2025
- FPMAJ Calls for Expanded Range of Selection for Comparator Drugs
June 16, 2025
- PMP Drugs Should Be Excluded from Price Revisions: FPMAJ Committee Chief
June 16, 2025
- Mitsubishi’s BRD4 Degrader Now in US PI/II for Solid Tumors
June 16, 2025
- JPMA Ready to Engage with Government on CEA Debates: Statement
June 16, 2025
- Sumitomo’s Myelofibrosis Drug Earns Fast-Track Tag in US
June 16, 2025
- Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
- Novartis Makes Full Foray into Nephrology Space with Fabhalta: Exec
June 16, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…